Related Experiment Video
Updated: Sep 11, 2025

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
Published on: March 4, 2016
Extensive Arteriovenous Fistula Thrombosis With Glucagon-Like Peptide-1 Agonist
Muhammad Muneeb1, Elizabeth Choi2, Coralys Rodriguez3
1Internal Medicine, Trinity Health Oakland/Wayne State University, Pontiac, USA.
Abstract:
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used due to their significant anti-atherosclerotic, cardiovascular, and renoprotective benefits. However, potential adverse effects must also be considered. Here, we present a rare case of GLP-1 receptor agonist-induced thrombotic complications in a middle-aged African American female, contributing to the limited existing literature on this topic. A 55-year-old African American female with a past medical history of deceased donor renal transplantation presented with pain, swelling, and erythema localized to the left arteriovenous (AV) fistula. She also reported fever, chills, and the absence of a palpable thrill over the fistula for approximately one week before presentation. On physical examination, she exhibited significant swelling of the left upper limb with no detectable thrill over the AV fistula. Venous and arterial Doppler ultrasound of the left upper extremity revealed extensive thrombosis involving the left AV fistula, brachiocephalic vein, and both the radial and ulnar arteries. An extensive prothrombotic workup, including evaluations for inherited and acquired hypercoagulable states, was unremarkable. The only notable change in her medical regimen was a recent dose escalation of her GLP-1 receptor agonist. Given the temporal association and absence of alternative causes, the thrombosis was attributed to the GLP-1 receptor agonist, which was subsequently discontinued. No further thrombotic events occurred during follow-up. This case highlights one of the rare thrombotic events of commonly used drugs, such as GLP-1 receptor agonists. This case also underscores the importance of life-threatening events of commonly used drugs, adding to the existing literature.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hemodialysis I: Introduction
Hypoglycemia and Glucagon
Peripheral Artery Disease V: Postoperative Nursing Management
Dipeptidyl Peptidase 4 Inhibitors
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

